BioCentury
ARTICLE | Strategy

Shifting MS spending

How the multiple sclerosis market slowdown will affect new entrants

August 17, 2015 7:00 AM UTC

Payers are finally getting - and using - the tools to end uninterrupted price increases for multiple sclerosis drugs as a result of an abundance of options, greater willingness to steer prescribing choices, and the entrance of the first generic for the leading treatment in the category.

Specialty drugs are among payers' most expensive and fastest growing categories; however, signs are appearing that MS - one of the most expensive - is about to experience a significant slowdown...